AB024.Phenotypic dissection of myocilin(MYOC)-induced glaucoma reveals that the modifier of glaucoma 1(MOG1)locus encodes a gene which prevents ocular hypertension

Background:Pathogenic mechanisms leading to open-angle glaucoma(OAG)are genetically complex.They involve neuroinflammation,elevation of intra-ocular pressures(IOP)and optic nerve hypersensitivity to cellular stresses.We mapped a locus at chromosome 20q13 that contains a modifier gene for glaucoma severity.While searching for its identity,we named this gene modifier of glaucoma 1(MOG1).The goal of this study is to characterize the mechanism by which MOG1 delays the age of onset of glaucoma when OAG is caused by mutations in the MYOC gene.We hypothesized that MOG1 mechanism may be linked to a specific endophenotype and thus dissected ocular phenotypes present in a large French-Canadian MYOC glaucoma pedigree.Methods:We studied 375 members of the CA pedigree in which autosomal dominant OAG is caused by the MYOCK423E mutation.In this family,wild-type MOG1(normal form)delays the age-at-onset(AAO)of glaucoma.Ocular records of MYOCK423E carriers were reviewed to extract the values of four quantitative traits portraying four endophenotypes:(I)age of maximal intra-ocular pressure(IOP max),(II)IOP progression,(III)rate of optic nerve degeneration and,(IV)AAO defined as the age at which IOP≥22 mmHg or age at which optic disk degeneration was first detected.Endophenotypes were tested for their heritability.A three-stage algorithm was designed to detect double mutants who carry the MYOCK423E mutation and putative MOG1 mutations.Quantitative traits values of double-mutants were then compared.Results:We found 156 individuals who were heterozygotes(HTZ)for MYOCK423E.One hundred and twenty of these were classified affected as they were OAG or had treatment for ocular hypertension(OHT)with IOP≥22 mmHg.The other 36 HTZ were asymptomatic.Only two endophenotypes,AAO and IOP max,showed significant heritability.OHT was the 1st symptom detected in 99%of the affecteds;it always preceded optic nerve damage.AAO of the affecteds ranged from 7 to 63 years old while rates of optic nerve degeneration did not significantly change between them.When comparing the AAOs of the double mutants(those who are MYOCK423E HTZ+MOG1 mutant)with the median AAOs of their respective neighbors(≤1st cousins)who are MYOCK423E HTZ and MOG1 wild-type(called single mutant as they carry a normal MOG1),we observed that the ages-at-onset of OHT in the double mutants were on average 8 years younger than the median of AAOs in their respective single mutant neighbors.Conclusions:These findings demonstrate that age-at-onset(AAO)is a reliable endophenotype to use for discovering the effect of putative MOG1 mutations in MYOCK423E carriers.They also show that the wild-type form of MOG1 delays the AAO of myocilin-induced glaucoma by about 8 years.Our study further suggests that wild-type MOG1 acts on intra-ocular pressures(IOP)by counteracting ocular hypertension(OHT)caused by mutant myocilin proteins before the beginning of optic nerve degeneration.

AB090. MOG1, the genetic modifier at 20q13, delays the age-at-onset of glaucoma by 8 to 10 years

Background:Primary open-angle glaucoma(POAG)is a genetically complex disorder caused primarily by gene-gene interactions.To identify these interactions,we studied the CA family,a large French-Canadian pedigree in which the myocilin K423E mutation(MYOCK423E)causes autosomal dominant glaucoma with diagnoses ranging from juvenile-onset OAG(JOAG)to late adult-onset POAG in the heterozygotes(HTZ).To explain this extreme variability,we hypothesized that a second gene,called a modifier,was interacting with MYOC,the primary disease gene.Our goals were(I)to map the modifier on the human genome and;(II)to characterize the symptoms affected genetically by the modifier.These symptoms are called endophenotypes.Methods:Three hundred seventy-five CA members were studied using four quantitative endophenotypes:age of maximal intra-ocular pressures(IOPmax),IOPs progression,progression of cup to disk ratios and age-at-onset(AAO)defined as age at which ocular hypertension(OHT)was first detected with IOP≥22 mmHg.Genome-wide linkage analysis was performed by genotyping 408 genetic markers in 184 CA members.An unbiased pedigree-based algorithm was designed to identify the individuals who were double-mutants,i.e.,these individuals carried one MYOCK423E mutation(i.e.,they were HTZ,affected or not)and they also carry simultaneously a DNA mutation within the modifier.Results:Out of the 375 CA family members investigated,156 were HTZ for the MYOCK423E mutation.120 HTZ were affected with OAG or OHT with treatment while the remaining 36 HTZ were asymptomatic.AAO ranged from 7 to 63 years old;4 individuals over 50 years old were still asymptomatic.OHT preceded optic nerve damage in>98%of the HTZ carriers,confirming that AAO reflected the true severity of the disorder.The modifier showed strong inherited effects on 2 of the 4 endophenotypes:AAO and IOPmax.We next mapped with very high confidence the modifier locus for AAO at chromosome 20q13.Saturation genotyping with additional markers refined the locus to a 9 to 10 centimorgan interval,or about 10 million DNA nucleotides,between D20S857 and D20S832.The locus was named modifier of glaucoma 1(MOG1).When comparing the AAOs of the double mutants versus the median of the AAOs of the MYOCK423E HTZ who carried a wild-type(normal)MOG1 gene and were 1st cousins or closer with the double mutant under investigation,we observed that MOG1 delayed the ages at onset by an average of 8 to 10 years in the double mutants.Conclusions:The MOG1 locus encodes a DNA element that delays the onset of glaucoma by an average of 8-10 years by hampering the first manifestations of OHT.This research will lead to the development of new therapeutic targets for glaucoma.These treatments should prevent optic nerve damage by maintaining IOPs within the normal range.